Jim Simons Rockwell Medical, Inc. Transaction History

Renaissance Technologies LLC

$63.4 Billion
Q4 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Rockwell Medical, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 442,350 shares of RMTI stock, worth $809,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

442,350

Previous 114,672 285.75%

Holding current value

$809,500

Previous $455,000 98.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$2.01 - $4.65 $658,632 - $1.52 Million	327,678 Added 285.75%	442,350 $902,000
Q3 2024 Nov 13, 2024	BUY	$1.67 - $4.4 $19,993 - $52,676	11,972 Added 11.66%	114,672 $455,000
Q2 2024 Aug 09, 2024	BUY	$1.45 - $1.92 $133,674 - $177,002	92,189 Added 877.07%	102,700 $180,000
Q1 2024 May 13, 2024	SELL	$1.23 - $1.86 $107,857 - $163,101	-87,689 Reduced 89.3%	10,511 $17,000
Q4 2023 Feb 13, 2024	BUY	$1.58 - $2.44 $132,968 - $205,343	84,157 Added 599.28%	98,200 $186,000
Q3 2023 Nov 14, 2023	SELL	$1.83 - $6.19 $613,181 - $2.07 Million	-335,072 Reduced 95.98%	14,043 $29,000
Q2 2023 Aug 11, 2023	BUY	$1.8 - $5.46 $486,720 - $1.48 Million	270,400 Added 343.52%	349,115 $1.91 Million
Q1 2023 May 12, 2023	BUY	$1.03 - $2.62 $43,038 - $109,476	41,785 Added 113.15%	78,715 $142,000
Q4 2022 Feb 13, 2023	SELL	$0.84 - $1.39 $239 - $396	-285 Reduced 0.77%	36,930 $37,000
Q3 2022 Nov 14, 2022	BUY	$1.2 - $2.11 $2,640 - $4,642	2,200 Added 6.28%	37,215 $49,000
Q2 2022 Aug 12, 2022	BUY	$1.28 - $4.84 $44,819 - $169,472	35,015 New	35,015 $45,000

Others Institutions Holding RMTI

# of Institutions

Shares Held

8.96M

Call Options Held

339K

Put Options Held

43.3K

View Full List

About ROCKWELL MEDICAL, INC.

Ticker RMTI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 10,675,200
Market Cap $19.5M
Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iro...

More about RMTI

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account